UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K
-------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): SEPTEMBER 21, 2004
KERYX BIOPHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE 000-30929 13-4087132
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
750 LEXINGTON AVENUE
NEW YORK, NEW YORK 10022
(Address of Principal Executive Offices)
(212) 531-5965
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[] Written communications pursuant to Rule 425 under the Securities
Act.
[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
[] Pre-commencement communications pursuant to Rule 14d-2b under the
Exchange Act.
[] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act.
ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS.
(b) On September 21, 2004, Mr. Peter M. Kash resigned as a member of the
Board of Directors of Keryx Biopharmaceuticals, Inc. ("Keryx") and as the
Chairman of the Audit Committee. Dr. Lindsay A. Rosenwald, a current independent
member of the Board of Directors, will serve as interim Chairman of the Audit
Committee. The text of a press release, dated September 22, 2004, announcing the
resignation is attached as Exhibit 99.1 and is incorporated by reference into
this Item.
(d) On September 21, 2004, Dr. Eric Rose was appointed to the Board of
Directors of Keryx by unanimous vote of the directors. There are no arrangements
or understandings between Dr. Rose and any other person pursuant to which Dr.
Rose was appointed to the Board. Since January 1, 2004, Dr. Rose has not entered
into any transactions with Keryx and is not currently considering any such
transactions. The text of a press release announcing the appointment of Dr. Rose
is attached as Exhibit 99.1 and is incorporated by reference into this Item.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
The following exhibit is filed as a part of this report:
EXHIBIT
NUMBER DESCRIPTION
------ -----------
99.1 Press Release dated September 22, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
KERYX BIOPHARMACEUTICALS, INC.
(Registrant)
Date: September 22, 2004
By: /s/ Ron Bentsur
----------------------------------
Ron Bentsur
Vice President Finance and
Investor Relations
INDEX TO EXHIBITS
EXHIBIT
NUMBER DESCRIPTION
------ -----------
99.1 Press Release dated September 22, 2004.